MARKET

DRMAW

DRMAW

Dermata Therapeutics Inc
NASDAQ
0.0203
0.0000
0.00%
Closed 09:30 05/16 EDT
OPEN
0.0203
PREV CLOSE
0.0203
HIGH
0.0203
LOW
0.0203
VOLUME
0
TURNOVER
--
52 WEEK HIGH
0.0440
52 WEEK LOW
0.0070
MARKET CAP
--
P/E (TTM)
-0.0025
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DRMAW last week (0505-0509)?
Weekly Report · 4d ago
Weekly Report: what happened at DRMAW last week (0428-0502)?
Weekly Report · 05/05 11:43
Weekly Report: what happened at DRMAW last week (0421-0425)?
Weekly Report · 04/28 11:55
Weekly Report: what happened at DRMAW last week (0414-0418)?
Weekly Report · 04/21 11:54
Dermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference At 4 Weeks
Benzinga · 04/15 12:42
DERMATA THERAPEUTICS INC - ANNOUNCES TOPLINE RESULTS FROM PHASE 3 TRIAL OF XYNGARI - SEC FILING
Reuters · 04/15 12:32
Weekly Report: what happened at DRMAW last week (0407-0411)?
Weekly Report · 04/14 11:41
Weekly Report: what happened at DRMAW last week (0331-0404)?
Weekly Report · 04/07 11:41
More
About DRMAW
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.

Webull offers Dermata Therapeutics Inc stock information, including NASDAQ: DRMAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRMAW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DRMAW stock methods without spending real money on the virtual paper trading platform.